Rachel Henson

TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.

TL;DR: Exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, is performed to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondaryFLT3 mutations.

TL;DR: This work performed whole exome and RNA-sequencing of these rare hematologic malignancies and present the most complete survey of the genomic landscape of these diseases to date, finding a diversity of combinatorial mutational patterns that generally do not cluster within any one diagnosis.

TL;DR: A large functional genomic resource is expanded, avenues for mechanistic exploration and drug development, and tools for predicting outcome in AML are revealed, including a single gene, PEAR1, which is found to be among the strongest predictors of patient survival.